RNA Virus Infections
Conditions
Interventions
This is an observational retrospective and prospective cohort study to evaluate the humoral response in six groups exposed to the most widely used COVID-19 immunization regimens in Brazil: two standa
G12.513
D020133
Sponsors
Fundação Oswaldo Cruz
Fundação Oswaldo Cruz
Eligibility
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Men and women aged 18 years and over; A resident of the metropolitan region of Rio de Janeiro or the state of Ceará; Have received at least one dose of ChAdOx1-nCov19 (AstraZeneca-Oxford /Fiocruz) or Coronavac (Butantan) vaccine in the states of Rio de Janeiro or Ceará; Accept to participate in the study by signing the Informed Consent Form.
Exclusion criteria
Exclusion criteria: Men and women with unavailability to comply with the follow-up schedule
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Evaluation of the spike protein-specific anti-SARS-CoV 2 IgG titer after each vaccination regimen | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary Outcome 1: Describe the time to seroconversion of spike protein-specific anti-SARS-CoV 2 IgG antibodies after vaccination;Secondary Outcome 2: Analyze the cellular immunity after 3, 6 and 9 months of vaccination with the 3rd dose of the vaccine;Secondary Outcome 3: Verify the frequency of adverse events from COVID-19 vaccination;Secondary Outcome 4: Verify the frequency of positive RT-PCR examination, after vaccination and over one year after vaccination 3rd dose of vaccine;Secondary Outcome 5: Verify the time between positive RT-PCR test and 1st, 2nd and/or 3rd dose of vaccination and throughout one year after the 3rd dose of the vaccine;Secondary Outcome 6: Identify the titer of neutralizing antibodies after the 1st, 2nd and 3rd dose of vaccination | — |
Countries
Brazil
Contacts
Public ContactAndre Daher
Fundação Oswaldo Cruz
Outcome results
None listed